HEMATOLOGICAL MALIGNANCIES
Clinical trials for HEMATOLOGICAL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGICAL MALIGNANCIES trials appear
Sign up with your email to follow new studies for HEMATOLOGICAL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug DS3790a enters human trials for blood cancers
Disease control Recruiting nowThis study tests a new drug called DS3790a in people with blood cancers. The goal is to check its safety and how well it works, alone or with other treatments. About 420 adults will take part. The study is currently recruiting.
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 26, 2026 04:04 UTC
-
Can a lower dose of transplant drug boost quality of life for older cancer patients?
Disease control Recruiting nowThis study looks at whether a lower dose of a common transplant drug can help older adults (60+) feel better after a stem cell transplant for blood cancers. The goal is to prevent graft-versus-host disease while improving quality of life. About 126 participants will receive eithe…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New pill HMPL-506 takes on tough blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests an experimental pill called HMPL-506 for people with certain blood cancers (like AML and ALL) that have come back or not responded to treatment. The main goals are to check the drug's safety and find the right dose. About 132 adults will take part in …
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Hutchmed • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New antibody drug shows promise for Hard-to-Treat blood cancer
Disease control Recruiting nowThis study tests a new drug called talquetamab for people with multiple myeloma, a type of blood cancer, that has returned or not responded to other treatments. The drug is designed to help the immune system attack cancer cells. About 510 participants will receive the drug to see…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New drug combo targets blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called ICP-248, alone or with another drug, for people with certain blood cancers (B-cell malignancies). The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 191 adults aged 18 to 80 will take part.
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE1 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Can nurse chats ease kids' cancer journey? new trial aims to find out.
Symptom relief Recruiting nowThis study tests a program where specially trained nurses start conversations about palliative care early after a child's cancer diagnosis. The goal is to see if this improves the child's quality of life and reduces symptoms. About 120 children with solid tumors or blood cancers …
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated May 18, 2026 12:03 UTC
-
Massive study aims to unlock secrets of early blood cancers
Knowledge-focused Recruiting nowThis study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers want to understand why some cases progress and others don't. Participants provide extra blood, bone marrow, or cheek swab samples during routine care. N…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated May 26, 2026 04:04 UTC
-
15-Year watch begins for CAR T-Cell therapy recipients
Knowledge-focused Recruiting nowThis study follows about 546 people who have already received a Galapagos CAR T-cell therapy for blood cancers. Researchers will track them for 15 years to check for long-term side effects, how long the treatment lasts in the body, and overall survival. No new treatment is given—…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE3 • Sponsor: Lakefront Biotherapeutics NV • Aim: Knowledge-focused
Last updated May 26, 2026 03:57 UTC